Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

LOUISVILLE, Ky. -- An investigational fixed-dose combination of a short-acting beta 2-adrenergic agonist and an inhaled corticosteroid appeared to slow the deterioration in lung function and reduce ...

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

LONDON, April 12 (Reuters) - Treating COVID-19 patients at home with a commonly-used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on Monday which ...

A total of 332 patients entered the study and 277 patients were randomised and treated, 137 with FP250µg twice daily via Diskus TM inhaler and 140 with budesonide 600µg twice daily via Turbuhaler TM.